Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million

Stock Information for Sol-Gel Technologies Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sol-Gel Technologies Ltd.

Sol-Gel Announces Reverse Share Split
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa
Sol-Gel Technologies Announces Management Realignment

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.